| CORMEDIX INC. DL-,001 |
| USA |
| Gesundheit |
| US21900C3088 / A2PF3G |
| 19KA (Frankfurt) / CRMD (NASDAQ) |
| FRA:19KA, ETR:19KA, 19KA:GR, NASDAQ:CRMD |
| - |
| http://www.cormedix.com/ |
|
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial ..
>Volltext.. |
| 396.01 Mio. EUR |
| 297 Mio. EUR |
| 414.94 Mio. EUR |
| 226.68 Mio. EUR |
| 168.01 Mio. EUR |
| 2.18 EUR |
| 130.29 Mio. EUR |
| 231.01 Mio. EUR |
| 227.67 Mio. EUR |
| 1.37 |
| 292.47% |
| 277.37% |
| - |
| - |
| - |
| - |
| CORMEDIX |
| 09.11.26 |
|
||||
|
||||
|
||||
|